{"id":"W2063331655","doi":"10.2147/tcrm.s38852","title":"Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab","year":2013,"lang":"en","type":"review","venue":"Therapeutics and Clinical Risk Management","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Adalimumab; Medicine; Infliximab; Golimumab; Ulcerative colitis; Adverse effect; Biologic Agents; Tumor necrosis factor alpha; Clinical trial; Vedolizumab; Crohn's disease; Disease; Intensive care medicine; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004405068,0.0003675702,0.0006759349,0.00006301244,0.00006613391,0.00004176346,0.0002842468,0.0002041211,0.000007690104],"category_scores_gemma":[0.000008754934,0.0002274005,0.0002685542,0.00008070396,0.00006720914,0.000002000657,0.00009744053,0.0001274461,0.00003541361],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005081163,"about_ca_system_score_gemma":0.00007587202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001375456,"about_ca_topic_score_gemma":0.00009583072,"domain_scores_codex":[0.9976747,0.0006430929,0.000752329,0.0004964576,0.0001837228,0.0002496975],"domain_scores_gemma":[0.9989476,0.00009593019,0.0002768106,0.0005492104,0.00004079443,0.00008964456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003533866,0.0005434398,0.00007149921,0.0003654089,0.00100364,0.00002813851,0.0001052564,0.000008239686,3.03159e-8,0.0008732989,0.00008485134,0.9965628],"study_design_scores_gemma":[0.001293279,0.001194214,0.004774585,0.0006331001,0.0009278465,0.00000136422,0.0001017512,0.00001060072,0.000001849987,0.0004289504,0.9902949,0.000337511],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01838472,0.9669697,0.00008574408,0.00007103418,0.0002432909,0.006647691,0.0002565121,0.00001231409,0.007328956],"genre_scores_gemma":[0.004121519,0.9941335,0.0002580181,0.0003735079,0.00007767784,0.0004778754,0.00006453456,0.00003323514,0.0004601809],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9962253,"threshold_uncertainty_score":0.9273124,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06120196587115313,"score_gpt":0.3745149900067927,"score_spread":0.3133130241356396,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}